![ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)](https://www.urotoday.com/images/stories/conferences/esmo/esmo_2014_P12-2-poster_final.jpg)
ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Omniscope on X: "Delighted to be showcasing our use of integrated modelling to identify clonotypes of response at ESMO Immuno-Oncology Congress 2023 We will be present at Thursday's poster session and throughout
![VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines](https://www.vbivaccines.com/wp-content/uploads/2020/09/ESMO-2020-Poster.png)
VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines
![Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting - anaveon Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting - anaveon](https://anaveon.com/wp-content/uploads/2023/10/023-10-23-ESMO-2023-poster-ANV419-001-.png)
Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting - anaveon
Imugene Limited - Our ESMO Asia 2019 poster presentation is now available for download http://ow.ly/NPEX50xhTvR | ASX: IMU #Oncology #BioTech #EndCancer #Immunotherapy #Cancer | Facebook
![Poster presented at ESMO 2018 Congress: 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid Poster presented at ESMO 2018 Congress: 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid](https://aslanpharma.com/wp-content/uploads/2018/10/ASLAN001-002SG-300x150.png)
Poster presented at ESMO 2018 Congress: 430P - Phase I study: Safety and tolerability of Varlitinib (VAR) in combination with Oxaliplatin and Capecitabine (COX) or Oxaliplatin and 5-FU (FOL) in advanced solid
![ESMO distinguishes Diana Martins (IPATIMUP) with the "Best Poster Award" in the category of Breast Cancer | ASPIC ESMO distinguishes Diana Martins (IPATIMUP) with the "Best Poster Award" in the category of Breast Cancer | ASPIC](https://www.aspic.pt/sites/default/files/styles/node_detail/public/field/image/news-dianamartinsESMO.png?itok=9MObMZ5p)